Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-04-15

Clinical Trial Update: Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) [Phase 3]

View source ↗

Summary

Phase 3 results update for sitagliptin cardiovascular outcomes study (MK-0431-082) in type 2 diabetes mellitus; trial completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sitagliptin (sitagliptin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2016-04-15